A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer.

@article{Chi2012API,
  title={A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer.},
  author={Kim Nguyen Chi and Martin E. Gleave and Ladan Fazli and S. Larry Goldenberg and Alan So and Christian K. Kollmannsberger and Nevin Murray and Anna V. Tinker and Michael Pollak},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 12},
  pages={
          3407-13
        }
}
PURPOSE Activation of the insulin-like growth factor 1 receptor (IGF-IR) is implicated in prostate cancer development and progression. This study evaluated biologic and clinical effects of figitumumab, a fully human monoclonal IGF-IR antibody, in patients with localized prostate cancer. EXPERIMENTAL DESIGN Eligible patients received figitumumab 20 mg/kg intravenously every 3 weeks for 3 cycles followed by prostatectomy. The primary endpoint was IGF-IR expression inhibition as assessed by… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

New incriminating evidence against IGF2.

  • Translational cancer research
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2015
VIEW 3 EXCERPTS

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

Antitumour activity of MDV 3100 in castrationresistant prostate cancer : a phase 1 - 2 study

HI Scher, TM Beer, +3 authors E Efstathiou
  • Lancet
  • 2010

An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2007
VIEW 1 EXCERPT